Table 1.
Baseline Demographic and Disease Characteristics of the Study Patients (N = 65)
| Characteristic | No. of Patients | % |
|---|---|---|
| Sex | ||
| Women | 32 | 49 |
| Men | 33 | 51 |
| Race | ||
| White | 56 | 86 |
| Black or African American | 4 | 6 |
| Asian | 2 | 3 |
| Other | 3 | 5 |
| Ethnicity | ||
| Hispanic | 17 | 26 |
| Not Hispanic | 48 | 74 |
| Age, years | ||
| Median | 31 | |
| Range | 19 to 83 | |
| 18-29 | 29 | 45 |
| 30-59 | 28 | 43 |
| ≥ 60 | 8 | 12 |
| ECOG performance status at baseline | ||
| 0 or 1 | 50 | 77 |
| 2 or 3 | 15 | 23 |
| Prior VCR exposure | ||
| Yes | 65 | 100 |
| No | 0 | 0 |
| Prior HCT | ||
| Yes | 31 | 48 |
| No | 34 | 52 |
| Ongoing neuropathy sign or symptom at baseline | ||
| Yes | 50 | 76.9 |
| No | 15 | 23.1 |
| ALL lineage | ||
| B cell | 55 | 85 |
| T cell | 10 | 15 |
| Extramedullary disease at baseline | ||
| Yes | 10 | 15 |
| No | 55 | 85 |
| Number of prior lines of anti-ALL therapy | ||
| 2 | 32 | 49 |
| 3 | 24 | 37 |
| ≥ 4 | 9 | 14 |
| Refractory to immediate prior line of therapy | ||
| Yes | 29 | 45 |
| No | 36 | 55 |
| Baseline bone marrow leukemic blasts, % | ||
| Median | 82 | |
| Range | 1 to 99 | |
| > 50 | 52 | 80 |
| ≤ 50 | 13 | 20 |
| Baseline bone marrow cytogenetics | ||
| Unfavorable | 33 | 51 |
| Intermediate | 23 | 35 |
| Favorable | 0 | 0 |
| Not available | 9 | 14 |
Abbreviations: ALL, acute lymphoblastic leukemia; ECOG, Eastern Cooperative Oncology Group; HCT, hematopoietic cell transplantation; VCR, vincristine.